AGP Executive Report
Last update: 9 hours agoOsteoporosis Drug Update: The European Commission has authorized CinnaGen’s Zandoriah® (teriparatide) for adult osteoporosis, giving an EU-wide marketing route that also covers Liechtenstein (with local requirements still applying). Rare Disease Hope: Neuren’s Rett syndrome therapy Daybu (trofinetide) is back on track after a positive European Medicines Agency CHMP opinion, with the European Commission expected to make a final decision soon—potentially the first EU treatment for neurobehavioral symptoms in eligible patients. Cross-Border Care Basics: A new explainer breaks down how cross-border healthcare works across Europe—who can use it, what costs are covered, when prior approval is needed, and how to claim. Public Health Leadership: A WHO overview highlights how the agency coordinates global responses to infectious threats, from outbreak containment to vaccines, medicines, and support for health systems. Heat & Safety: With Europe facing another heatwave, a look back at the 2003 disaster asks why air conditioning is still uncommon and points to risks for vulnerable groups like older adults and outdoor workers. Accessibility While Traveling: Guidance notes that people with a UK Blue Badge can use it in some European countries, including Liechtenstein, under reciprocal parking arrangements. Health-Adjacent Travel Disruption: Australians are warned of long delays at European airports as the EU’s Entry/Exit System rolls out, affecting non-EU travel through Schengen.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
